title: Combination use of anti-CD133 antibody and SSA lectin can effectively enrich cells with high tumorigenicity.
abstract: Glycans exhibit characteristic changes in their structures during development and thus have been used as markers for stem/progenitor cells. However, the glycan structures unique to cancer stem cells (CSC) remain unknown. In the present study, we examined glycan structures in CD133+ CD13+ CSC, which were recently found to have a high CSC ability, by means of a lectin microarray. Seven sialylated glycan-recognizing lectins, MAL-I, SNA, SSA, TJA-I, ACG, ABA and MAH, showed higher affinity to CD133+ CD13+ CSC than CD133+ cells with a lower CSC ability. In addition, we demonstrated that CD133+ SSA+ cells isolated from Huh7 cells had a significantly higher ability to form tumors in non-obese diabetic/severe combined immunodeficiency disease (NOD/SCID) mice and spheres under serum-free conditions than CD133+ SSA- cells. These results suggest that hepatic CSC highly express sialylated glycans and that SSA lectin can be used as a tool for isolating CSC. This study is the first report to demonstrate the characteristic glycan structures in CSC and to indicate a new methodology involving lectins for isolating CSC.
authors.affiliation: Department of Molecular Biochemistry and Clinical Investigation, Osaka University Graduate School of Medicine, Osaka, Japan.
authors.forename: Kenta
authors.initials: K
authors.lastname: Moriwaki
authors.forename: Kumiko
authors.initials: K
authors.lastname: Okudo
authors.forename: Naotsugu
authors.initials: N
authors.lastname: Haraguchi
authors.forename: Shunsaku
authors.initials: S
authors.lastname: Takeishi
authors.forename: Hiromichi
authors.initials: H
authors.lastname: Sawaki
authors.forename: Hisashi
authors.initials: H
authors.lastname: Narimatsu
authors.forename: Masahiro
authors.initials: M
authors.lastname: Tanemura
authors.forename: Hideshi
authors.initials: H
authors.lastname: Ishii
authors.forename: Masaki
authors.initials: M
authors.lastname: Mori
authors.forename: Eiji
authors.initials: E
authors.lastname: Miyoshi
mesh_terms: D000071916:AC133 Antigen; D000818:Animals; D000906:Antibodies / Q000276:immunology; D015703:Antigens, CD / Q000737:chemistry* / Q000276:immunology*; D014408:Biomarkers, Tumor; D018826:CD13 Antigens / Q000276:immunology*; D002469:Cell Separation / Q000379:methods*; D005434:Flow Cytometry; D006023:Glycoproteins / Q000737:chemistry* / Q000276:immunology*; D037102:Lectins; D051379:Mice; D016688:Mice, Inbred NOD; D016513:Mice, SCID; D046228:Microarray Analysis; D014411:Neoplastic Stem Cells / Q000737:chemistry / Q000166:cytology* / Q000276:immunology; D010455:Peptides / Q000737:chemistry* / Q000276:immunology*; D016133:Polymerase Chain Reaction; D011134:Polysaccharides / Q000737:chemistry* / Q000276:immunology
chemical_list: D000071916:AC133 Antigen; D000906:Antibodies; D015703:Antigens, CD; D014408:Biomarkers, Tumor; D006023:Glycoproteins; D037102:Lectins; D010455:Peptides; D011134:Polysaccharides; C000606024:Prom1 protein, mouse; D018826:CD13 Antigens